Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Cancer
RVMDRevolution Medicines IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for RMC-6236 (RASMULTI) in Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Cancer. The expected timing is based on the latest available company guidance and may change.
10/23/24- Safety & efficacy data from Ph1 study of PDAC at AACR-NCI-EORTC. 12/2/24- Ph1/1b update on monotherapy in 2L metastatic PDAC supports ongoing Ph3 RASolute 302 clinical trial. Ph1/1b proof-of-concept monotherapy in previously treated NSCLC supports Ph3 RASolve 301. 03/17/26:- Present daraxonrasib Ph1/2 datasets at AACR Apr 20-21, 2026. 04/21/26:- 1L metastatic PDAC data: ORR 58% combo; ORR 47% monotherapy at AACR. 05/06/26:- NEJM published RMC-6236-001 (NCT05379985) Ph1/2 PDAC cohort results for daraxonrasib. 06/24/26:- Ph1/2 zoldonrasib+dara combo data in 2L+ KRAS G12D mPDAC presented July 2, 2026. 07/02/26:- ESMO GI: zoldonrasib+dara ORR 50% in 2L, 47% in 3L+ KRAS G12D mPDAC.
Verification
Confirm timing and program details against the company announcement or filing.